We conducted a prospective single-blind randomized study to assess whether a single 80,000 IU dose of human recombinant erythropoietin ( HRE ) , given just 2 days before cardiac surgery , could be effective in reducing perioperative allogeneic red blood cell transfusion ( aRBCt ) .